- Home
- PPBT vs IBG Comparison
PPBT vs IBG Comparison
Compare PPBT & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- IBG
- Stock Information
- Founded
- PPBT 2010
- IBG 2018
- Country
- PPBT Israel
- IBG Australia
- Employees
- PPBT N/A
- IBG N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- IBG Beverages (Production/Distribution)
- Sector
- PPBT Health Care
- IBG Consumer Staples
- Exchange
- PPBT Nasdaq
- IBG Nasdaq
- Market Cap
- PPBT 6.2M
- IBG 5.4M
- IPO Year
- PPBT N/A
- IBG 2024
- Fundamental
- Price
- PPBT $2.31
- IBG $0.64
- Analyst Decision
- PPBT Strong Buy
- IBG Strong Buy
- Analyst Count
- PPBT 1
- IBG 1
- Target Price
- PPBT $33.00
- IBG N/A
- AVG Volume (30 Days)
- PPBT 269.4K
- IBG 680.2K
- Earning Date
- PPBT 08-06-2025
- IBG 08-26-2025
- Dividend Yield
- PPBT N/A
- IBG N/A
- EPS Growth
- PPBT N/A
- IBG N/A
- EPS
- PPBT N/A
- IBG N/A
- Revenue
- PPBT N/A
- IBG $2,931,243.00
- Revenue This Year
- PPBT N/A
- IBG N/A
- Revenue Next Year
- PPBT N/A
- IBG N/A
- P/E Ratio
- PPBT N/A
- IBG N/A
- Revenue Growth
- PPBT N/A
- IBG N/A
- 52 Week Low
- PPBT $2.00
- IBG $0.44
- 52 Week High
- PPBT $13.95
- IBG $3.35
- Technical
- Relative Strength Index (RSI)
- PPBT 49.88
- IBG N/A
- Support Level
- PPBT $2.11
- IBG N/A
- Resistance Level
- PPBT $2.31
- IBG N/A
- Average True Range (ATR)
- PPBT 0.16
- IBG 0.00
- MACD
- PPBT 0.01
- IBG 0.00
- Stochastic Oscillator
- PPBT 72.73
- IBG 0.00
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.